On the criteria used for assessing the risk of bias in randomized trials included in systematic reviews and meta-analyses addressing adverse effects
Date
2015Source
European journal of epidemiologyVolume
30Issue
3Pages
249-250Google Scholar check
Keyword(s):
Metadata
Show full item recordCollections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Efficacy and safety of more intensive lowering of LDL cholesterol [1]
Bonovas, Stefanos; Nikolopoulos, Georgios K.; Sitaras, N. M. (2011)
-
Article
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: Pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
Fountzilas, George; Dafni, U.; Bobos, M.; Kotoula, V.; Batistatou, Anna; Xanthakis, I.; Papadimitriou, C.; Kostopoulos, I.; Koletsa, T.; Tsolaki, E.; Televantou, D.; Timotheadou, E.; Koutras, A. K.; Klouvas, G. D.; Samantas, E.; Pisanidis, N.; Karanikiotis, C.; Sfakianaki, I.; Pavlidis, Nicholas; Gogas, H.; Linardou, H.; Kalogeras, K. T.; Pectasides, Dimitrios; Dimopoulos, M. A. (2013)Background: The HER2 gene has been established as a valid biological marker for the treatment of breast cancer patients with trastuzumab and probably other agents, such as paclitaxel and anthracyclines. The TOP2A gene has ...
-
Article
Developing the evidence base for cancer chemoprevention: Use of meta-analysis
Nikolopoulos, Georgios K.; Bagos, Pantelis G.; Bonovas, Stefanos (2011)Meta-analysis is a quantitative approach for systematically combining the results of previous studies in order to arrive at conclusions about the body of research. It answers a specific research question, includes an ...